CoChat

Curcumin improves sclerosing cholangitis in Mdr2 −/− mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation

Open access
Baghdasaryan, Anna, Claudel, Thierry, Kosters, Astrid, Gumhold, Judith, Silbert, Dagmar, Thüringer, Andrea, Leski, Katharina, Fickert, Peter, Karpen, Saul J, Trauner, Michael · 2010 · Gut
Cited by 96

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Background and aim: Chronic cholangiopathies have limited therapeutic options and represent an important indication for liver transplantation. Curcumin, the yellow pigment of the spice turmeric, has pleiotropic actions and attenuates hepatic damage in animal models of chemically-induced liver injury. Whether curcumin has beneficial effects in cholangiopathies is unknown. Methods: Potential anticholestatic, anti-inflammatory and antifibrotic mechanisms of curcumin were explored in vivo in Mdr2 −/− mice as a murine model of chronic cholangiopathy; as well as in vitro in a cholangiocyte cell line (HuCCT1) and portal myofibroblasts (MFBs) isolated from Mdr2 −/− mice. Results: Liver damage, cholestasis and fibrosis were reduced in Mdr2 −/− mice after curcumin feeding. Moreover, curcumin inhibited cholangiocyte proliferation and expression of activation marker vascular cell adhesion molecule-1 in Mdr2 −/− mice. Curcumin—similar to PPARγ synthetic agonist troglitazone—directly inhibited TNF-α-induced inflammatory activation of cholangiocytes in vitro, whereas these beneficial effects of curcumin were largely blocked by a PPARγ synthetic antagonist. In addition, curcumin blocked proliferation and activation of portal MFBs by inhibiting ERK1/2 phosphorylation, thus contributing to reduced fibrogenesis. Conclusions: These results show that curcumin may have multiple targets in liver including activation of PPARγ in cholangiocytes and inhibition of ERK1/2 signalling in MFBs, thereby modulating several central cellular events in a mouse model of cholangiopathy. Targeting these pathways may be a promising therapeutic approach to cholangiopathies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gut.2009.186528

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 96

Metadata

Authors
Baghdasaryan, A., Claudel, T., Kosters, A., Gumhold, J., Silbert, D., Thüringer, A., Leski, K., Fickert, P., Karpen, S. J., & Trauner, M.
Venue
Gut
Publisher
BMJ
Published
2010-03-23
Volume
59
Issue
4
Pages
521-530
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2138950515
Cited by
96
References
13
FWCI
5.83
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Curcumin improves sclerosing cholangitis in Mdr2 −/− mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. https://app.cochat.ai/papers/10.1136/gut.2009.186528
The paper
Baghdasaryan, A., Claudel, T., Kosters, A., Gumhold, J., Silbert, D., Thüringer, A., Leski, K., Fickert, P., Karpen, S. J., & Trauner, M. (2010). Curcumin improves sclerosing cholangitis in Mdr2 −/− mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut. https://doi.org/10.1136/gut.2009.186528

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.